Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sosei Group ( (JP:4565) ).
Nxera Pharma has achieved a significant development milestone in its collaboration with Eli Lilly, targeting diabetes and metabolic diseases. This milestone, achieved through Nxera’s NxWave™ platform, validates their drug design capabilities and results in an undisclosed payment from Lilly. The collaboration, initiated in 2022, aims to leverage Nxera’s expertise in GPCR-focused drug design and Lilly’s development and commercialization capabilities. This achievement positions Nxera for potential future milestones and royalties, enhancing its industry positioning and offering promising implications for stakeholders.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. The company has established a commercial business in Japan to develop and commercialize innovative medicines and has a pipeline of over 30 active programs targeting neurology, metabolic diseases, and immunology. Nxera employs approximately 400 people across key locations and is listed on the Tokyo Stock Exchange.
YTD Price Performance: -13.36%
Average Trading Volume: 956,140
Technical Sentiment Signal: Sell
Current Market Cap: Yen82.07B
Find detailed analytics on 4565 stock on TipRanks’ Stock Analysis page.